Rifampin Prophylaxis for Contacts of Haemophilus influenzae Type b Disease

Frederick Cox, Rose Trincher, J. Peter Rissing, Maurice Patton, George H. Mccracken, Dan M. Granoff

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Rifampin prophylaxis (20 mg/kg once daily for four days) was used in close contacts of children with Haemophilus influenzae type b (HIB) disease. Two hours after a dose, the concentration of rifampin in serum and saliva exceeded the minimum bactericidal concentrations of organisms obtained from four of the carriers. In both a randomized prospective and an open study, nasopharyngeal carriage was eradicated in 37 (95%) of 39 contacts. No cases of serious H influenzae disease occurred in four to six months of follow-up. At the dose and treatment schedule used, rifampin was safe and effective for eradication of HIB carriage. (JAMA 1981;245:1043-1045).

Original languageEnglish (US)
Pages (from-to)1043-1045
Number of pages3
JournalJAMA: The Journal of the American Medical Association
Issue number10
StatePublished - Mar 13 1981

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Rifampin Prophylaxis for Contacts of Haemophilus influenzae Type b Disease'. Together they form a unique fingerprint.

Cite this